Thought Leadership

Latest Report


Vantage Pharma, Biotech and Medtech 2018 in Review

Biopharma in 2018: Year of contrasts as stocks and M&A slump, but venture financing and IPOs remain strong The Vantage 2018 in Review paints a mixed picture for biopharma and medtech in 2018. Key indicators on share price and dealmaking showed weakness, but there are signs of health from the industry in IPO outcomes, venture financing…

Report library


Vantage 2019 Preview

2019 expected to be volatile year for pharma and biotech industries The Vantage 2019 Preview looks at the risks and opportunities for the year ahead. Report…